About 5 to 10 percent of all breast cancers are caused by inherited gene mutations passed down through families. The remaining 90 to 95 percent are considered sporadic, meaning they develop from genetic changes that happen during a person’s lifetime rather than being inherited at birth. That number surprises many people, since breast cancer “running in the family” gets a lot of attention, but the vast majority of cases occur in women with no family history at all.
Inherited vs. Acquired Mutations
Every cancer starts with a DNA mutation, but the origin of that mutation matters. Inherited (germline) mutations are present in a parent’s egg or sperm cell, so they exist in every cell of the child’s body from conception. These can be passed to the next generation. Acquired (somatic) mutations happen randomly in ordinary body cells at some point after birth, often from accumulated damage over decades. They affect only the cells that descend from the original mutated cell, and they cannot be passed to children.
When people ask whether breast cancer is “genetic,” they usually mean the inherited kind. But sporadic breast cancers are also driven by genetic changes in the tumor cells themselves. The distinction is whether you were born with the mutation or whether it arose later in life. Only the inherited type shows up on genetic testing done through a blood or saliva sample, and only the inherited type raises concerns for other family members.
BRCA1 and BRCA2: The Highest-Risk Genes
The two most well-known breast cancer genes, BRCA1 and BRCA2, account for the largest share of hereditary cases. More than 60 percent of women who carry a harmful change in either gene will develop breast cancer during their lifetime, compared to about 13 percent of women in the general population. These genes normally help repair damaged DNA in cells. When they don’t work properly, errors accumulate and cancer becomes far more likely.
BRCA mutations are relatively rare in the general population, affecting roughly 1 in 400 people. But certain ethnic groups carry them at much higher rates. Among people of Ashkenazi Jewish descent, about 1 in 40 carries a BRCA mutation, making genetic testing especially relevant for that population.
Moderate-Risk Genes
BRCA1 and BRCA2 get the most attention, but several other inherited gene mutations also raise breast cancer risk, just not as dramatically. Research modeling lifetime risk by age 80 puts the numbers in perspective:
- PALB2 mutations: roughly 50 percent lifetime risk of breast cancer
- CHEK2 mutations: about 30 percent lifetime risk
- ATM mutations: about 28 percent lifetime risk
- BRCA1 and BRCA2 mutations: approximately 74 percent lifetime risk
These moderate-risk genes are individually rarer than BRCA mutations, but collectively they contribute a meaningful share of hereditary breast cancers. Genetic testing panels now routinely screen for all of them, not just BRCA1 and BRCA2. If you have a strong family history but test negative for BRCA, one of these genes could still be involved.
Triple-Negative Breast Cancer and Genetics
Certain breast cancer subtypes are more likely to have a genetic link. Triple-negative breast cancer, a more aggressive form that lacks three common receptors targeted by standard therapies, has a stronger-than-average association with inherited mutations. About 10 to 15 percent of triple-negative breast cancers in white women test positive for BRCA1 mutations. In Black women, that figure jumps to around 35 percent. This disparity has led to recommendations for broader genetic testing in women diagnosed with triple-negative breast cancer regardless of family history.
Family History Without a Known Mutation
Here’s where it gets complicated: having a family history of breast cancer does raise your risk even if no identifiable gene mutation shows up on testing. An estimated 15 to 20 percent of breast cancers occur in women who have a close relative with the disease but carry no detectable high-risk mutation. This “familial” category likely involves combinations of many small genetic variations, each contributing a modest amount of risk, along with shared environmental and lifestyle factors within families. Current genetic tests can’t fully explain this clustering, which is why family history remains an important part of risk assessment even when test results come back negative.
What This Means for Screening
If you have a first-degree relative (mother, sister, or daughter) with breast cancer, your own risk is roughly double that of someone without such a history. If two first-degree relatives have been diagnosed, the risk triples. These numbers hold true whether or not a specific gene mutation has been identified.
Genetic testing is most useful when there are clear red flags in a family: breast cancer diagnosed before age 50, multiple relatives on the same side of the family with breast or ovarian cancer, a male relative with breast cancer, or Ashkenazi Jewish ancestry. A positive result doesn’t mean cancer is inevitable, but it does open the door to earlier and more frequent screening, risk-reducing medications, and in some cases preventive surgery. A negative result in a high-risk family still warrants closer monitoring than average, since not all genetic contributors have been identified yet.
For the roughly 90 percent of breast cancers that aren’t driven by an inherited mutation, the usual risk factors apply: aging, hormone exposure, alcohol use, obesity after menopause, and physical inactivity. These are areas where lifestyle changes can meaningfully shift your odds.